Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.

Journal: Lung cancer (Amsterdam, Netherlands)
PMID: 39752796

Abstract

BACKGROUND: Artificial intelligence (AI) models are emerging as promising tools to identify predictive features among data coming from health records. Their application in clinical routine is still challenging, due to technical limits and to explainability issues in this specific setting. Response to standard first-line immunotherapy (ICI) in metastatic Non-Small-Cell Lung Cancer (NSCLC) is an interesting population for machine learning (ML), since up to 30% of patients do not benefit.

Authors

  • Francesca Rita Ogliari
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: francescaritaogliari@gmail.com.
  • Alberto Traverso
    Maastricht University Medical Centre, Netherlands.
  • Simone Barbieri
    Università Vita-Salute San Raffaele, Milan, Italy.
  • Marco Montagna
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Internal Medicine, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Filippo Chiabrando
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Internal Medicine, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Enrico Versino
    Università Vita-Salute San Raffaele, Milan, Italy.
  • Antonio Bosco
    Microsoft Corporation, Milan, Italy.
  • Alessia Lin
    Microsoft Corporation, Milan, Italy.
  • Roberto Ferrara
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
  • Sara Oresti
    Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Giuseppe Damiano
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Maria Grazia Viganò
    Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Michele Ferrara
    Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Silvia Teresa Riva
    Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Antonio Nuccio
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Francesco Maria Venanzi
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Davide Vignale
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Giuseppe Cicala
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Anna Palmisano
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Stefano Cascinu
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vanesa Gregorc
    Unit of Oncology and Haematology, Candiolo Cancer Institute, FPO-IRCCS, Italy.
  • Alessandra Bulotta
    Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Antonio Esposito
    Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Carlo Tacchetti
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Michele Reni
    Università Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Keywords

External Resources

Popular Topics
Recent Journals